AUPH
Price
$8.64
Change
+$0.01 (+0.12%)
Updated
Jun 27 closing price
Capitalization
1.17B
31 days until earnings call
KRYS
Price
$138.88
Change
-$3.70 (-2.60%)
Updated
Jun 27 closing price
Capitalization
4.01B
42 days until earnings call
Interact to see
Advertisement

AUPH vs KRYS

Header iconAUPH vs KRYS Comparison
Open Charts AUPH vs KRYSBanner chart's image
Aurinia Pharmaceuticals
Price$8.64
Change+$0.01 (+0.12%)
Volume$4.37M
Capitalization1.17B
Krystal Biotech
Price$138.88
Change-$3.70 (-2.60%)
Volume$418.51K
Capitalization4.01B
AUPH vs KRYS Comparison Chart in %
Loading...
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AUPH vs. KRYS commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUPH is a Buy and KRYS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (AUPH: $8.64 vs. KRYS: $138.88)
Brand notoriety: AUPH and KRYS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUPH: 349% vs. KRYS: 112%
Market capitalization -- AUPH: $1.17B vs. KRYS: $4.01B
AUPH [@Biotechnology] is valued at $1.17B. KRYS’s [@Biotechnology] market capitalization is $4.01B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUPH’s FA Score shows that 0 FA rating(s) are green whileKRYS’s FA Score has 0 green FA rating(s).

  • AUPH’s FA Score: 0 green, 5 red.
  • KRYS’s FA Score: 0 green, 5 red.
According to our system of comparison, KRYS is a better buy in the long-term than AUPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUPH’s TA Score shows that 5 TA indicator(s) are bullish while KRYS’s TA Score has 4 bullish TA indicator(s).

  • AUPH’s TA Score: 5 bullish, 5 bearish.
  • KRYS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, AUPH is a better buy in the short-term than KRYS.

Price Growth

AUPH (@Biotechnology) experienced а +9.09% price change this week, while KRYS (@Biotechnology) price change was +4.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

AUPH is expected to report earnings on Jul 31, 2025.

KRYS is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($4.01B) has a higher market cap than AUPH($1.17B). KRYS (33.30) and AUPH (31.93) have similar P/E ratio . AUPH YTD gains are higher at: -3.786 vs. KRYS (-11.349). KRYS has higher annual earnings (EBITDA): 140M vs. AUPH (65.9M). KRYS has more cash in the bank: 617M vs. AUPH (313M). KRYS has less debt than AUPH: KRYS (9.66M) vs AUPH (77.9M). KRYS has higher revenues than AUPH: KRYS (333M) vs AUPH (247M).
AUPHKRYSAUPH / KRYS
Capitalization1.17B4.01B29%
EBITDA65.9M140M47%
Gain YTD-3.786-11.34933%
P/E Ratio31.9333.3096%
Revenue247M333M74%
Total Cash313M617M51%
Total Debt77.9M9.66M806%
FUNDAMENTALS RATINGS
AUPH vs KRYS: Fundamental Ratings
AUPH
KRYS
OUTLOOK RATING
1..100
5039
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
71
Overvalued
PROFIT vs RISK RATING
1..100
10041
SMR RATING
1..100
6457
PRICE GROWTH RATING
1..100
4662
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
24n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AUPH's Valuation (69) in the Biotechnology industry is in the same range as KRYS (71) in the Pharmaceuticals Major industry. This means that AUPH’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (41) in the Pharmaceuticals Major industry is somewhat better than the same rating for AUPH (100) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than AUPH’s over the last 12 months.

KRYS's SMR Rating (57) in the Pharmaceuticals Major industry is in the same range as AUPH (64) in the Biotechnology industry. This means that KRYS’s stock grew similarly to AUPH’s over the last 12 months.

AUPH's Price Growth Rating (46) in the Biotechnology industry is in the same range as KRYS (62) in the Pharmaceuticals Major industry. This means that AUPH’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as AUPH (100) in the Biotechnology industry. This means that KRYS’s stock grew similarly to AUPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AUPHKRYS
RSI
ODDS (%)
Bearish Trend 4 days ago
86%
Bullish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
86%
Momentum
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
81%
MACD
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
78%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 11 days ago
77%
Declines
ODDS (%)
Bearish Trend 14 days ago
84%
Bearish Trend 14 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
80%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AICGX37.170.12
+0.32%
American Century Discplnd Cor Val R5
CDCRX11.500.03
+0.26%
Copeland Dividend Growth Fund Class C
FAVAX24.150.05
+0.21%
Fidelity Advisor Equity Value A
AWIIX16.140.03
+0.19%
CIBC Atlas Income Opportunities Instl
JNBAX10.130.01
+0.10%
JPMorgan Income Builder A

AUPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUPH has been loosely correlated with SHJBF. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if AUPH jumps, then SHJBF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUPH
1D Price
Change %
AUPH100%
+0.12%
SHJBF - AUPH
38%
Loosely correlated
N/A
KRYS - AUPH
37%
Loosely correlated
-2.60%
CRDF - AUPH
36%
Loosely correlated
-0.32%
NAMS - AUPH
35%
Loosely correlated
+0.65%
TGTX - AUPH
35%
Loosely correlated
-3.24%
More

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with XNCR. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
-2.60%
XNCR - KRYS
54%
Loosely correlated
-3.10%
IDYA - KRYS
54%
Loosely correlated
-4.13%
CRNX - KRYS
54%
Loosely correlated
-0.10%
ACLX - KRYS
54%
Loosely correlated
+0.90%
CGON - KRYS
54%
Loosely correlated
-0.46%
More